TG02

Ligand id: 9095

Name: TG02

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 0
Topological polar surface area 50.28
Molecular weight 372.2
XLogP 4.65
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Synonyms
compound 26h [PMID: 22148278] | SB-1317 | SB1317 | TG-02
Database Links
BindingDB Ligand 50363196
CAS Registry No. 937270-47-8 (source: PubChem)
ChEMBL Ligand CHEMBL1944698
PubChem CID 16739650
Search Google for chemical match using the InChIKey VXBAJLGYBMTJCY-NSCUHMNNSA-N
Search Google for chemicals with the same backbone VXBAJLGYBMTJCY
Search UniChem for chemical match using the InChIKey VXBAJLGYBMTJCY-NSCUHMNNSA-N
Search UniChem for chemicals with the same backbone VXBAJLGYBMTJCY
Comments
TG02 is an orally active multi-kinase inhibitor, with a unique activity profile against CDKs, JAK2 and FLT3 [4-5]. Like pacritinib it is a small molecule macrocycle. TG02 was rationally designed to inhibit several key signaling pathways simultaneously with the aim of maximising anti-cancer efficacy. It is being investigated for its anti-leukemic potential [2-3].
The compound is administered as the citrate salt.